

Can and should evidence / preferences collected from patients tilt the board in favour of accepting a new technology?



Moderator: Elisabeth Oehrlein

Panellists: Paola Kruger, Giovanni Mauri, Andrea Marcellusi

ISPOR Europe 2019

Tuesday 5 November, 2019

Copenhagen



Welcome and introductions

MODERATOR

Elisabeth Oehrlein, PhD, MS

Senior Director, Research and Programs, National Health Council, Washington, DC, USA



Paola Kruger, MA

Patient Expert-EUPATI Fellow, Accademia dei Pazienti/EUPATI Italia, Rome, Italy



Giovanni Mauri, MD

Interventional Radiologist, European Institute of Oncology, Milan, Italy



Andrea Marcellusi, PhD


Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy



Today's focus



Explore challenges and opportunities in incorporating patient insights into HTA deliberations from a multi-stakeholder perspective



Discuss the 'weight' of the patient voice in decision making using a real-life case study to facilitate relevant and timely debate



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Housekeeping



PLEASE SILENT OR SWITCH OFF CELL PHONES

PLEASE FEEL FREE TO ASK QUESTIONS!



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Case study:

Ultrasound-guided ablation techniques in nodular thyroid disease

Giovanni Mauri



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Patient history (1)

- 57 year-old female
- No history of other diseases
- In 2005: diagnosis of thyroid nodular goiter, with large right lobe thyroid nodule
- Fine needle aspiration: benign nodule (thy 2)
- No symptoms



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Patient history (2)

- Slow growth over time of the right thyroid nodule
- In 2012: started complaining of neck discomfort (dysphagia) and aesthetic concerns
- Normal thyroid function tests
- Endocrinologist and surgeon suggested surgical thyroidectomy
- The patient refused, with the desire of avoiding invasive surgery and maintaining thyroid function




Ultrasound-guided radiofrequency ablation

- In 2013: ultrasound guided radiofrequency ablation
- Procedure is performed under local anesthesia, in outpatient setting
- A small needle is inserted into the nodule, and radiofrequency energy is applied to achieve the death of nodule cells



Ultrasound-guided radiofrequency ablation

- After 2 weeks: initial reduction of the nodule volume and improvement in symptoms
- At 6 months from treatment: complete disappearance of symptoms. Normal thyroid function. Volume reduction from 18.9 ml to 3.06 ml
- At 5 years from treatment: no symptoms, normal thyroid function



PATIENT FOCUSED
MEDICINES DEVELOPMENT



ISPOR
Improving healthcare decisions

J Clin Endocrinol Metab. 2014 Oct 99(10):3653-9. doi: 10.1210/jc.2014-1826. Epub 2014 Jul 22.

Long-term efficacy of ultrasound-guided laser ablation for benign solid thyroid nodules. Results of a three-year multicenter prospective randomized trial.

Papini E¹, Rago T, Gambelungho G, Valcavi R, Bizzarri G, Vitti P, De Feo P, Riganiti F, Misischì I, Di Stasio E, Pacella CM.

Korean J Endocrinol. 2018 Jan;Feb 16(1):147-174. doi: 10.3348/kj.2018.19.1.167. Epub 2018 Jan 2.

Quality of Life in Patients Treated with Percutaneous Laser Ablation for Non-Functioning Benign Thyroid Nodules: A Prospective Single-Center Study.

Oddo S¹, Felix E¹, Mussap M², Giusti M¹.

Int J Hyperthermia. 2018 Nov 15:1-5. [Epub ahead of print]

Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA).

Mauri G^{1,2}, Cova L³, Monaco CG⁴, Sconfienza LM^{2,5}, Corbetta S^{5,6}, Benedini S⁶, Ambrogi E⁷, Milani V⁷, Baroli A⁸, Ierace T⁹, Solbiati L^{9,10}.

Int J Hyperthermia. 2018 Jul;35(1):150-158. doi: 10.1080/02643758.2018.1485590. Epub 2018 Aug 15.

Patient satisfaction after thyroid RFA versus surgery for benign thyroid nodules: a telephone survey.

Bernardi S^{1,2}, Dobrinja C², Carere A¹, Giudici E³, Calabrò V², Zancanati F^{1,2}, de Manzini N^{1,2}, Fabris B^{1,2}, Stacul F⁴.

AJNR Am J Neuroradiol. 2015 Jul;36(7):1321-5. doi: 10.3174/ajnr.A4276. Epub 2015 Mar 26.

Treatment of Benign Thyroid Nodules: Comparison of Surgery with Radiofrequency Ablation.

Che Y¹, Jin S², Shi C³, Wang L⁴, Zhang X⁴, Lu Y⁵, Baek JH⁶.

J Clin Endocrinol Metab. 2015 Oct 100(10):3903-10. doi: 10.1210/jc.2015-1964. Epub 2015 Aug 14.

Outcomes and Risk Factors for Complications of Laser Ablation for Thyroid Nodules: A Multicenter Study on 1531 Patients.

Pacella CM¹, Mauri G¹, Achille G¹, Barbaro D¹, Bizzarri G¹, De Feo P¹, Di Stasio E¹, Esposito R¹, Gambelungho G¹, Misischì I¹, Raqqunli R¹, Rago T.

Best Pract Res Clin Endocrinol Metab. 2014 Aug;28(4):601-18. doi: 10.1016/j.beem.2014.02.004. Epub 2014 Mar 5.



PATIENT FOCUSED
MEDICINES DEVELOPMENT

The advent of ultrasound-guided ablation techniques in nodular thyroid disease: towards a patient-tailored approach.

Papini E¹, Pacella CM², Misischì I³, Guglielmi R³, Bizzarri G², Døssing H⁴, Hegedus L⁵.

Key messages: ultrasound-guided ablation techniques in nodular thyroid disease

- Ultrasound-guided ablation techniques are new minimally-invasive techniques that can be used to treat benign thyroid nodules
- Costs are similar to surgical thyroidectomy, however, QoL for the patient is improved
- Since costs are the same there is no incentive for hospitals to introduce it and change supplies and train staff
- However, patients prefer it on the basis of better QoL

Panel and Participant Discussion



Multi-stakeholder perspectives



VALUE

EVIDENCE

What is the value of incorporating patient evidence and preference into HTAs?

Do we have metrics and/or evidence?

Is there economic value?



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Patient and HCP perspectives



What are the potential consequences of NOT incorporating patient evidence/preference?



PATIENT FOCUSED
MEDICINES DEVELOPMENT



HTA perspective



METHODOLOGY

ALIGNMENT

What do HTA bodies consider robust patient evidence? What methodology should be used?

Does patient evidence/preference carry equal weight as other 'traditional' evidence – if not – why not?

Are different HTA bodies aligned in incorporation/use of patient evidence?



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Multi-stakeholder perspectives



Is better alignment and/or
standardization required?



PATIENT FOCUSED
MEDICINES DEVELOPMENT



Multi-stakeholder perspectives



What tools already exist?

GUIDANCE

TOOLS



PATIENT FOCUSED
MEDICINES DEVELOPMENT



What tools already exist ? The Toolbox

Inserting the Patient Voice

- Patient Perspectives on Disease Impact and Treatment Options: A Stratification Tool (NHC)
- Patient-Journey Mapping Toolbox (NHC)
- PFDD Meeting Resources (FasterCures)
- Real-World Evidence (NHC)

Capacity Building

- European Patients' Academy Toolbox (EUPATI)
- Clinical Outcome Assessment (NHC)

Guidances/Roadmaps/Rubrics

- FDA PFDD Guidances
- The Patient Engagement Quality Guidance (PFMD)
- Tackling Representativeness: A Roadmap and Rubric (NHC)

Planning

- Responsible Research and Innovation Toolkit (EPWS)

FMV and Legal

- Fair-Market Value Calculator (NHC)
- Sponsor-Patient Interactions During Drug Development: Good Practice
- Insights on Patient Engagement (NHC)
- Reasonable Legal Agreements (PFMD)



PFMD Patient Engagement Quality Guidance



76 participants from **51** organisations participated in **9** multistakeholder meetings (2016–2018).



A shortlist of **20** relevant PE initiatives (from **170** screened) were identified

PE Quality Guidance pilots are underway



The UK National Standards provided the main framework for the first draft of the PE Quality Guidance.



7 key PE Quality Criteria were identified



Public consultation yielded **67** responses from diverse backgrounds.



The PE Quality Guidance was agreed to be useful for achieving quality patient engagement in practice. It is comprehensive, understandable and easy to use.



8 initiatives were selected from various sources to be included in the BOGP based on their demonstration of one or more PE Quality Criteria.



**PATIENT FOCUSED
MEDICINES DEVELOPMENT**



Multi-stakeholder perspectives



**GUIDANCE
TOOLS**

**What tools or guidance are needed?
Who should be involved in co-developing these tools?**



**PATIENT FOCUSED
MEDICINES DEVELOPMENT**





Discussion



Thank you!

